Pharma & Biotech Patent Litigation in Europe Conference Returns with IPKat Readers’ Discount

Key Takeaways

• 10% IPKat reader discount with code D10-999-IPKAT26.
• Conference covers post‑BSH v Electrolux cross‑border enforcement strategies.
• Sessions on UPC preliminary injunctions and divergent standards.
• Analysis of antibody patent prosecution in EU and US.
• Discussion of skinny labels and second‑use patent liability.

Pulse Analysis

The European pharma and biotech patent arena is entering a period of rapid evolution, driven by landmark decisions from the Unified Patent Court (UPC) and national courts. By convening in Amsterdam, the Pharma & Biotech Patent Litigation in Europe conference provides a rare forum where practitioners can dissect the practical fallout from cases like BSH v Electrolux, which reshaped cross‑border enforcement tactics. Attendees gain insight into how divergent standards for preliminary injunctions at the UPC and national jurisdictions affect the timing and scope of enforcement actions, a critical factor for companies racing to protect high‑value biologics and small‑molecule drugs.

Beyond procedural nuances, the program delves into substantive patent law trends that directly influence R&D pipelines. Sessions on antibody patent prosecution compare EU and U.S. approaches, highlighting the growing importance of claim drafting that survives both jurisdictions. The doctrine of equivalence, now tested by the UPC’s inaugural rulings, is examined alongside contrasting UK and German jurisprudence, offering counsel a roadmap for navigating equivalence arguments. Recent G 1/24 and G 1/25 decisions further refine claim interpretation and description conflicts, signaling a new chapter for life‑science patents that could tighten or broaden protection scopes.

For industry stakeholders, the conference is more than an academic exercise; it informs commercial strategy. Understanding regulatory exclusivities after the EU Pharma Package and the potential safe harbour offered by skinny‑label second‑use patents can shape market entry plans and licensing negotiations. The IPKat‑exclusive discount lowers the barrier for smaller firms and in‑house teams to access this knowledge pool, fostering a more inclusive dialogue that may accelerate harmonization of litigation practices across Europe and the United States. Participants leave equipped to align legal tactics with business objectives, ultimately influencing the speed at which innovative therapies reach patients.